Key result
Everolimus-eluting stents and other second-generation devices combine the low restenosis rate of first-generation drug-eluting stents with improved long-term safety.
Why the study?
What are the safety, efficacy, and unique characteristics of everolimus-eluting stents compared to earlier stent generations?
What are the safety, efficacy, and unique characteristics of everolimus-eluting stents compared to earlier stent generations?
Everolimus-eluting stents represent a significant advancement in interventional cardiology by offering low restenosis rates alongside improved long-term safety compared to earlier stent generations.
Bare metal stents have a proven safety record, but limited long-term efficacy due to in-stent restenosis. First-generation drug-eluting stents successfully countered the restenosis rate, but were hampered by concerns about their long-term safety. Second generation drug-eluting stents have combined the low restenosis rate of the first generation with improved long-term safety. We review the evolution of drug-eluting stents with a focus on the safety, efficacy, and unique characteristics of everolimus-eluting stents.
No takes yet. Share an insight, caveat, or question.
Steinberg et al. (2012) conducted a review in Coronary artery disease. Everolimus-eluting stents vs. Bare metal and first-generation drug-eluting stents was evaluated. Everolimus-eluting stents and other second-generation devices combine the low restenosis rate of first-generation drug-eluting stents with improved long-term safety.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: